Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis.

Geusens P, Alten R, Rovensky J, Sloan VS, Krammer G, Kralidis G, Richardson P.

Int J Clin Pract. 2004 Nov;58(11):1033-41.

PMID:
15605667
2.

Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.

Matchaba P, Gitton X, Krammer G, Ehrsam E, Sloan VS, Olson M, Mellein B, Hoexter G, Orloff J, Garaud JJ.

Clin Ther. 2005 Aug;27(8):1196-214. Review.

PMID:
16199245
3.

Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.

Bannwarth B, Berenbaum F.

Expert Opin Investig Drugs. 2005 Apr;14(4):521-33. Review.

PMID:
15882125
4.

Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.

Zintzaras E, Dahabreh IJ, Giannouli S, Voulgarelis M, Moutsopoulos HM.

Clin Ther. 2008 Nov;30(11):1939-55. doi: 10.1016/j.clinthera.2008.11.007. Review.

PMID:
19108784
5.

Aceclofenac in the management of inflammatory pain.

Legrand E.

Expert Opin Pharmacother. 2004 Jun;5(6):1347-57. Review.

PMID:
15163279
6.

Lumiracoxib (Prexige): a new selective COX-2 inhibitor.

Mysler E.

Int J Clin Pract. 2004 Jun;58(6):606-11. Review.

PMID:
15311562
7.

Disease-modifying drugs in rheumatoid arthritis.

Rahman A, Ahmed S, Underwood M.

Practitioner. 2001 Dec;245(1629):1018-25. Review. No abstract available.

PMID:
11771221
Items per page

Supplemental Content

Write to the Help Desk